Skip to main content
NCBI home page
Journal of Neurology, Neurosurgery, and Psychiatry logoLink to Journal of Neurology, Neurosurgery, and Psychiatry
. 2003 Jun;74(6):779–783. doi: 10.1136/jnnp.74.6.779

p53, mdm2, EGFR, and msh2 expression in paired initial and recurrent glioblastoma multiforme

A Stark 1, P Witzel 1, R Strege 1, H Hugo 1, H Mehdorn 1
PMCID: PMC1738476  PMID: 12754350

Abstract

Background: The clinical course of glioblastoma multiforme is characterised by invasive growth and regular recurrence. Many genetic alteration have been identified in the genesis of the disease. However, information about immunohistochemical expression in recurrent lesions is sparse.

Objectives: To determine (1) whether the p53/mdm2/EGFR/msh2 expression pattern differs in initial v recurrent glioblastoma multiforme; (2) whether a possible change in expression correlates with prognostic variables (progression-free survival time, total survival time); and (3) whether chemotherapy in addition to surgery and radiotherapy influences the p53/mdm2/EGFR/msh2 expression profile.

Methods: 27 patients were studied. They met the following criteria: histologically confirmed diagnosis of glioblastoma multiforme (WHO IV); total tumour resection at initial craniotomy; at least one re-craniotomy for glioblastoma multiforme recurrence; age 21 years or older. All underwent radiotherapy of at least 54 Gy, and 17 received additional chemotherapy. Immunohistochemical staining of initial tumours and recurrences was done with the following monoclonal antibodies: anti-p53 (DO-1), anti-mdm2 (IF-2), anti-EGFR (H11), and anti-msh2 (AB-1).

Results: In comparison with the initial tumour, recurrent lesions were characterised by reduced expression of p53 (p < 0.0001) and msh2 (p = 0.0012), while the numbers of mdm2 (p = 0.02), EGFR (p < 0.0001), and msh2 positive specimens (p < 0.0001) were reduced. Chemotherapy was associated with reduced msh2 expression (p < 0.0001). Immunohistochemical variables were not associated with patient survival.

Conclusions: There are significant differences in the p53/mdm2/EGFR/msh2 expression patterns in initial v recurrent glioblastoma multiforme. There may be interactions between chemotherapy and changes in the msh2 expression.

Full Text

The Full Text of this article is available as a PDF (158.5 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bálint E E., Vousden K. H. Activation and activities of the p53 tumour suppressor protein. Br J Cancer. 2001 Dec 14;85(12):1813–1823. doi: 10.1054/bjoc.2001.2128. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Deininger M. H., Grote E., Wickboldt J., Meyermann R. Distinct radiochemotherapy protocols differentially influence cellular proliferation and expression of p53 and Bcl-2 in glioblastoma multiforme relapses in vivo. J Neurooncol. 2000 Jun;48(2):121–129. doi: 10.1023/a:1006462618800. [DOI] [PubMed] [Google Scholar]
  3. Eneström S., Vavruch L., Frånlund B., Nordenskjöld B. Ki-67 antigen expression as a prognostic factor in primary and recurrent astrocytomas. Neurochirurgie. 1998 Mar;44(1):25–30. [PubMed] [Google Scholar]
  4. Friedman H. S., McLendon R. E., Kerby T., Dugan M., Bigner S. H., Henry A. J., Ashley D. M., Krischer J., Lovell S., Rasheed K. DNA mismatch repair and O6-alkylguanine-DNA alkyltransferase analysis and response to Temodal in newly diagnosed malignant glioma. J Clin Oncol. 1998 Dec;16(12):3851–3857. doi: 10.1200/JCO.1998.16.12.3851. [DOI] [PubMed] [Google Scholar]
  5. Hurtt M. R., Moossy J., Donovan-Peluso M., Locker J. Amplification of epidermal growth factor receptor gene in gliomas: histopathology and prognosis. J Neuropathol Exp Neurol. 1992 Jan;51(1):84–90. doi: 10.1097/00005072-199201000-00010. [DOI] [PubMed] [Google Scholar]
  6. Kleihues P., Ohgaki H. Primary and secondary glioblastomas: from concept to clinical diagnosis. Neuro Oncol. 1999 Jan;1(1):44–51. doi: 10.1093/neuonc/1.1.44. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Kolodner R. D., Marsischky G. T. Eukaryotic DNA mismatch repair. Curr Opin Genet Dev. 1999 Feb;9(1):89–96. doi: 10.1016/s0959-437x(99)80013-6. [DOI] [PubMed] [Google Scholar]
  8. Leung S. Y., Chan T. L., Chung L. P., Chan A. S., Fan Y. W., Hung K. N., Kwong W. K., Ho J. W., Yuen S. T. Microsatellite instability and mutation of DNA mismatch repair genes in gliomas. Am J Pathol. 1998 Oct;153(4):1181–1188. doi: 10.1016/S0002-9440(10)65662-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Michael Dan, Oren Moshe. The p53 and Mdm2 families in cancer. Curr Opin Genet Dev. 2002 Feb;12(1):53–59. doi: 10.1016/s0959-437x(01)00264-7. [DOI] [PubMed] [Google Scholar]
  10. Newcomb E. W., Cohen H., Lee S. R., Bhalla S. K., Bloom J., Hayes R. L., Miller D. C. Survival of patients with glioblastoma multiforme is not influenced by altered expression of p16, p53, EGFR, MDM2 or Bcl-2 genes. Brain Pathol. 1998 Oct;8(4):655–667. doi: 10.1111/j.1750-3639.1998.tb00191.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Nieder C., Petersen S., Petersen C., Thames H. D. The challenge of p53 as prognostic and predictive factor in gliomas. Cancer Treat Rev. 2000 Feb;26(1):67–73. doi: 10.1053/ctrv.1999.0145. [DOI] [PubMed] [Google Scholar]
  12. Ralte A. M., Sharma M. C., Karak A. K., Mehta V. S., Sarkar C. Clinicopathological features, MIB-1 labeling index and apoptotic index in recurrent astrocytic tumors. Pathol Oncol Res. 2001;7(4):267–278. doi: 10.1007/BF03032383. [DOI] [PubMed] [Google Scholar]
  13. Reifenberger J., Ring G. U., Gies U., Cobbers L., Oberstrass J., An H. X., Niederacher D., Wechsler W., Reifenberger G. Analysis of p53 mutation and epidermal growth factor receptor amplification in recurrent gliomas with malignant progression. J Neuropathol Exp Neurol. 1996 Jul;55(7):822–831. doi: 10.1097/00005072-199607000-00007. [DOI] [PubMed] [Google Scholar]
  14. Schiebe M., Ohneseit P., Hoffmann W., Meyermann R., Rodemann H. P., Bamberg M. Analysis of mdm2 and p53 gene alterations in glioblastomas and its correlation with clinical factors. J Neurooncol. 2000 Sep;49(3):197–203. doi: 10.1023/a:1006410702284. [DOI] [PubMed] [Google Scholar]
  15. Sehgal A. Molecular changes during the genesis of human gliomas. Semin Surg Oncol. 1998 Jan-Feb;14(1):3–12. doi: 10.1002/(sici)1098-2388(199801/02)14:1<3::aid-ssu2>3.0.co;2-f. [DOI] [PubMed] [Google Scholar]
  16. Simmons M. L., Lamborn K. R., Takahashi M., Chen P., Israel M. A., Berger M. S., Godfrey T., Nigro J., Prados M., Chang S. Analysis of complex relationships between age, p53, epidermal growth factor receptor, and survival in glioblastoma patients. Cancer Res. 2001 Feb 1;61(3):1122–1128. [PubMed] [Google Scholar]
  17. Strik H., Deininger M., Streffer J., Grote E., Wickboldt J., Dichgans J., Weller M., Meyermann R. BCL-2 family protein expression in initial and recurrent glioblastomas: modulation by radiochemotherapy. J Neurol Neurosurg Psychiatry. 1999 Dec;67(6):763–768. doi: 10.1136/jnnp.67.6.763. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Velasco Alfredo, Hewitt Stephen M., Albert Paul S., Hossein M., Rosenberg Helmar, Martinez Carlos, Sagalowsky Arthur I., McConnell John D., Marston W., Leach Fredrick S. Differential expression of the mismatch repair gene hMSH2 in malignant prostate tissue is associated with cancer recurrence. Cancer. 2002 Feb 1;94(3):690–699. doi: 10.1002/cncr.10247. [DOI] [PubMed] [Google Scholar]
  19. Zacksenhaus E., Gill R. M., Phillips R. A., Gallie B. L. Molecular cloning and characterization of the mouse RB1 promoter. Oncogene. 1993 Sep;8(9):2343–2351. [PubMed] [Google Scholar]
  20. von Deimling A., Louis D. N., Wiestler O. D. Molecular pathways in the formation of gliomas. Glia. 1995 Nov;15(3):328–338. doi: 10.1002/glia.440150312. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Neurology, Neurosurgery, and Psychiatry are provided here courtesy of BMJ Publishing Group

RESOURCES